Heparin modified polyethylene glycol microparticle aggregates for focal cancer chemotherapy

F. Philipp Seib, Mikhail Tsurkan, Uwe Freudenberg, David L. Kaplan, Carsten Werner

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Focal cancer therapy can improve clinical outcomes. Here, we evaluated injectable heparin-containing hydrogel material loaded with doxorubicin as a focal breast cancer therapy. We utilized a binary heparin/polyethylene glycol (PEG) hydrogel that was processed post synthesis into hydrogel microparticle aggregates to yield a readily injectable hydrogel. When loaded with doxorubicin, the injectable hydrogel microparticle aggregates had excellent short- and long-term anticancer activity against human breast cancer cells in vitro. Efficacy as a focal anticancer therapy was also evaluated in vivo by local injection of the doxorubicin-loaded PEG-heparin hydrogel microparticle aggregates into mice with established human orthotopic breast tumours. Animals showed significant antitumour responses by reduction in both primary tumour growth and metastasis when compared to animals which received the equivalent doxorubicin dose via an intravenous bolus injection. Overall, PEG-heparin hydrogel microparticle aggregates are emerging as a potential anticancer drug delivery system for focal therapy.
LanguageEnglish
Pages2287-2293
Number of pages7
JournalACS Biomaterials Science & Engineering
Volume2
Issue number12
DOIs
Publication statusPublished - 21 Oct 2016

Fingerprint

Chemotherapy
Hydrogel
Hydrogels
Polyethylene glycols
Heparin
Drug Therapy
Doxorubicin
Neoplasms
Injections
Breast Neoplasms
Tumors
Animals
Therapeutics
Drug Delivery Systems
Human Activities
Intravenous Injections
Cells
Neoplasm Metastasis
Growth

Keywords

  • breast cancer
  • hydrogel
  • microparticle drug delivery

Cite this

Seib, F. Philipp ; Tsurkan, Mikhail ; Freudenberg, Uwe ; Kaplan, David L. ; Werner, Carsten. / Heparin modified polyethylene glycol microparticle aggregates for focal cancer chemotherapy. In: ACS Biomaterials Science & Engineering. 2016 ; Vol. 2, No. 12. pp. 2287-2293.
@article{878d94421fcc4f42a785d4019abb8d6c,
title = "Heparin modified polyethylene glycol microparticle aggregates for focal cancer chemotherapy",
abstract = "Focal cancer therapy can improve clinical outcomes. Here, we evaluated injectable heparin-containing hydrogel material loaded with doxorubicin as a focal breast cancer therapy. We utilized a binary heparin/polyethylene glycol (PEG) hydrogel that was processed post synthesis into hydrogel microparticle aggregates to yield a readily injectable hydrogel. When loaded with doxorubicin, the injectable hydrogel microparticle aggregates had excellent short- and long-term anticancer activity against human breast cancer cells in vitro. Efficacy as a focal anticancer therapy was also evaluated in vivo by local injection of the doxorubicin-loaded PEG-heparin hydrogel microparticle aggregates into mice with established human orthotopic breast tumours. Animals showed significant antitumour responses by reduction in both primary tumour growth and metastasis when compared to animals which received the equivalent doxorubicin dose via an intravenous bolus injection. Overall, PEG-heparin hydrogel microparticle aggregates are emerging as a potential anticancer drug delivery system for focal therapy.",
keywords = "breast cancer, hydrogel, microparticle drug delivery",
author = "Seib, {F. Philipp} and Mikhail Tsurkan and Uwe Freudenberg and Kaplan, {David L.} and Carsten Werner",
note = "This document is the Accepted Manuscript version of a Published Work that appeared in final form in ACS Biomaterials Science & Engineering, copyright {\circledC} American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see http://pubs.acs.org/journal/abseba.",
year = "2016",
month = "10",
day = "21",
doi = "10.1021/acsbiomaterials.6b00495",
language = "English",
volume = "2",
pages = "2287--2293",
journal = "ACS Biomaterials Science & Engineering",
issn = "2373-9878",
publisher = "American Chemical Society",
number = "12",

}

Heparin modified polyethylene glycol microparticle aggregates for focal cancer chemotherapy. / Seib, F. Philipp; Tsurkan, Mikhail; Freudenberg, Uwe; Kaplan, David L.; Werner, Carsten.

In: ACS Biomaterials Science & Engineering, Vol. 2, No. 12, 21.10.2016, p. 2287-2293.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Heparin modified polyethylene glycol microparticle aggregates for focal cancer chemotherapy

AU - Seib, F. Philipp

AU - Tsurkan, Mikhail

AU - Freudenberg, Uwe

AU - Kaplan, David L.

AU - Werner, Carsten

N1 - This document is the Accepted Manuscript version of a Published Work that appeared in final form in ACS Biomaterials Science & Engineering, copyright © American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see http://pubs.acs.org/journal/abseba.

PY - 2016/10/21

Y1 - 2016/10/21

N2 - Focal cancer therapy can improve clinical outcomes. Here, we evaluated injectable heparin-containing hydrogel material loaded with doxorubicin as a focal breast cancer therapy. We utilized a binary heparin/polyethylene glycol (PEG) hydrogel that was processed post synthesis into hydrogel microparticle aggregates to yield a readily injectable hydrogel. When loaded with doxorubicin, the injectable hydrogel microparticle aggregates had excellent short- and long-term anticancer activity against human breast cancer cells in vitro. Efficacy as a focal anticancer therapy was also evaluated in vivo by local injection of the doxorubicin-loaded PEG-heparin hydrogel microparticle aggregates into mice with established human orthotopic breast tumours. Animals showed significant antitumour responses by reduction in both primary tumour growth and metastasis when compared to animals which received the equivalent doxorubicin dose via an intravenous bolus injection. Overall, PEG-heparin hydrogel microparticle aggregates are emerging as a potential anticancer drug delivery system for focal therapy.

AB - Focal cancer therapy can improve clinical outcomes. Here, we evaluated injectable heparin-containing hydrogel material loaded with doxorubicin as a focal breast cancer therapy. We utilized a binary heparin/polyethylene glycol (PEG) hydrogel that was processed post synthesis into hydrogel microparticle aggregates to yield a readily injectable hydrogel. When loaded with doxorubicin, the injectable hydrogel microparticle aggregates had excellent short- and long-term anticancer activity against human breast cancer cells in vitro. Efficacy as a focal anticancer therapy was also evaluated in vivo by local injection of the doxorubicin-loaded PEG-heparin hydrogel microparticle aggregates into mice with established human orthotopic breast tumours. Animals showed significant antitumour responses by reduction in both primary tumour growth and metastasis when compared to animals which received the equivalent doxorubicin dose via an intravenous bolus injection. Overall, PEG-heparin hydrogel microparticle aggregates are emerging as a potential anticancer drug delivery system for focal therapy.

KW - breast cancer

KW - hydrogel

KW - microparticle drug delivery

UR - http://pubs.acs.org/journal/abseba

U2 - 10.1021/acsbiomaterials.6b00495

DO - 10.1021/acsbiomaterials.6b00495

M3 - Article

VL - 2

SP - 2287

EP - 2293

JO - ACS Biomaterials Science & Engineering

T2 - ACS Biomaterials Science & Engineering

JF - ACS Biomaterials Science & Engineering

SN - 2373-9878

IS - 12

ER -